Adcendo Advances Three ADC Programs With Key Trial Milestones and FDA Orphan Status

New updates have been reported about Adcendo.

Adcendo has reported a series of clinical and regulatory milestones across its antibody-drug conjugate pipeline, underscoring a rapid build-out of its oncology franchise and greater regulatory de-risking. Lead asset ADCE-T02, a Topo-I inhibitor-based ADC targeting tissue factor in multiple solid tumors, has moved into the cohort expansion phase of the Phase I Tiffany-01 study, where two dose levels will be tested in randomized expansion cohorts to refine dose selection, safety, and durability of response.

To support this program, new ADCE-T02 preclinical data have been selected for presentation at the 2026 AACR Annual Meeting and accepted for publication in Molecular Cancer Therapeutics, with results highlighting strong in vivo efficacy across models and a favorable safety profile in non-human primates, potentially differentiating the asset against earlier TF-targeted ADCs. In parallel, ADCE-D01, a uPARAP-targeted ADC for mesenchymal tumors, has received U.S. FDA Orphan Drug Designation for soft tissue sarcoma, adding to prior Fast Track status and unlocking incentives such as tax credits and potential seven-year exclusivity, while a Phase I trial in metastatic or unresectable soft tissue sarcoma continues enrollment.

Adcendo also initiated clinical dosing for ADCE-B05, a first-in-class ADC aimed at an undisclosed target overexpressed in squamous cell tumors, with a first-in-human Phase I monotherapy trial now active at sites in the U.S. and Australia. Collectively, Adcendo is running three early-stage oncology trials in high unmet-need populations and intends to use proceeds from its recent Series C round to accelerate these programs, positioning the company to generate multiple human proof-of-concept readouts and enhance its strategic value as a clinical-stage ADC platform.

Management emphasizes that the combination of expanded trial activity, FDA designations, and high-profile scientific visibility at AACR and in a peer-reviewed journal strengthens the credibility of its ADC technology. For executives and investors, the key inflection points will center on emerging safety and efficacy data from the Tiffany-01, ADCElerate1, and ADCE-B05 trials, which will shape partnering potential, future financing needs, and the prioritization of indications across tissue factor, uPARAP, and squamous tumor targets.